Abstract
Abstract
Background
Traditional clinical trials require tests and procedures that are administered in centralized clinical research sites, which are beyond the standard of care that patients receive for their rare and chronic diseases. The limited number of rare disease patients scattered around the world makes it particularly challenging to recruit participants and conduct these traditional clinical trials.
Main body
Participating in clinical research can be burdensome, especially for children, the elderly, physically and cognitively impaired individuals who require transportation and caregiver assistance, or patients who live in remote locations or cannot afford transportation. In recent years, there is an increasing need to consider Decentralized Clinical Trials (DCT) as a participant-centric approach that uses new technologies and innovative procedures for interaction with participants in the comfort of their home.
Conclusion
This paper discusses the planning and conduct of DCTs, which can increase the quality of trials with a specific focus on rare diseases.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Genetics (clinical),General Medicine
Reference47 articles.
1. Global Genes RARE Disease Facts. https://globalgenes.org/rare-disease-facts/. Accessed 10 Oct 2022
2. Dockendorf MF, Hansen BJ, Bateman KP, Moyer M, Shah JK, Shipley LA. Digitally enabled, patient-centric clinical trials: shifting the Drug Development Paradigm. Clin Transl Sci. 2021;14:445–59.
3. Van Norman GA. Decentralized clinical trials. JACC Basic to Transl Sci. 2021;6:384–7.
4. US FDA. (2021) Digital Health Technologies for Remote Data Acquisition in Clinical Investigations.
5. US FDA. Enhancing the diversity of clinical trial populations — eligibility criteria. Enrollment Practices, and Trial Designs Guidance for Industry; 2020.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献